ONE-WAYDated event · through FY2025-H1
Development of PPMX-T002, a CDH3-targeted radiotherapeutic, in partnership with PPMX
A program to advance the preclinical and clinical development and out-licensing activities for PPMX-T002, a CDH3-targeted radiotherapeutic, in partnership with Perseus Proteomics. The radionuclide has been changed from 90Y to 225Ac, and development is being rebuilt from the preclinical stage.
Companies2How many companies write about this.
Threads3One company can carry more than one thread here.
PeriodFY2023 →Last written FY2025-H1
Directionhelps3 helps · 0 hurts · 0 flat